Tests ACT001 in adults with recurrent glioblastoma that has a STAT3-high signature
Tests ACT001 in adults whose glioblastoma returned after standard treatment.
Plain-language title generated from the registry record
Registry title: Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
Key facts
- Where
- Singapore, SingaporeSee the site
- Phase
- Phase 2
Where in Singapore
- National Neuroscience InstituteSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Neuroscience Institute
- Trial code
- NCT06894225
- Record updated
- 4 September 2026
- Original description
This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy.Read full original descriptionShow less
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy.
Inclusion: Histologically confirmed diagnosis of GBM according to 2021 WHO classification; Availability of tumor tissue representative of GBM from definitive surgery or biopsy and tested to harbour STAT3-High Signature; Previous treatment with at least radiation therapy; Documented recurrence of malignant glioma by diagnostic biopsy, resection or MRI performed within 21 days of study enrolment per RANO criteria; There is no limit on number of previous recurrences or lines of treatment; At least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) n new enhancement on MRI outside of the radiation treatment field; An interval of at least 4 weeks after the last administration of any investigational agent or any other treatment prior to first dose of STAT3 inhibitor; Age 21 years or older on the day of signing informed consent; Karnofsky performance status (KPS) of 70 or higher; Patient has adequate bone marrow, renal, and hepatic function ≤ 21 days prior to study enrolment (Step 2) as follows:; Absolute neutrophil count (ANC) ≥1,500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin (Hgb) ≥ 9.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb ≥ 9.0 g/dL is acceptable.); Renal function: calculated creatinine clearance ≥ 30 mL/min by the Cockcroft-Gault formula; Hepatic function: Total bilirubin, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) ≤ 1.5 times upper limit of normal (ULN). Patients with Gilbert's syndrome documented in medical history may be enrolled if bilirubin is < 3 times ULN.
Exclusion: Previous or current treatment with a JAK or STAT3 inhibitor; Previous or current treatment with bevacizumab/VEGF inhibitor; Presence of extracranial metastatic or leptomeningeal disease; Symptomatic intra-tumoural haemorrhage; Severe, active co-morbidity, defined as follows:; Patients with clinically defined Acquired Immune-Deficiency Syndrome (AIDS)-defining illness; Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the Investigator may put the patient at high risk of toxicity; Any other major medical illnesses or psychiatric impairments that in the Investigator's opinion will prevent administration or completion of protocol therapy; Patient is a lactating or pregnant female.